<DOC>
	<DOCNO>NCT01537107</DOCNO>
	<brief_summary>This phase I trial study side effect best dose sirolimus give together vismodegib treat patient solid tumor pancreatic cancer metastatic remove surgery . Sirolimus vismodegib may stop growth tumor cell block enzymes need cell growth</brief_summary>
	<brief_title>Sirolimus Vismodegib Treating Patients With Solid Tumors Pancreatic Cancer That Metastatic Can Be Removed By Surgery</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I . To determine maximally tolerate dose ( MTD ) combination vismodegib sirolimus unresectable solid tumor . ( Cohort I ) SECONDARY OBJECTIVES : I . To describe adverse event profile associate treatment combination . II . To describe tumor response treatment combination . CORRELATIVE OBJECTIVES : I . To assess effect sirolimus vismodegib combination select biomarkers tumor biopsy patient metastatic pancreatic cancer . II . To assess effect combination vismodegib sirolimus fludeoxyglucose F 18 ( F18-FDG ) positron emission tomography ( PET ) PET/computed tomography ( CT ) image Cohort II ( MTD ) patient metastatic pancreatic cancer . III . To study association clinical ( toxicity and/or tumor response activity ) biologic ( pharmacodynamic ) result obtain examine tissue biopsy PET PET/CT image patient . OUTLINE : This dose-escalation study sirolimus . Patients receive sirolimus orally ( PO ) daily ( QD ) vismodegib PO QD day 1-28 . Courses repeat every 28 day absence disease progression unacceptable toxicity . After completion study treatment , patient follow 3 month .</detailed_description>
	<mesh_term>Adenocarcinoma</mesh_term>
	<mesh_term>Pancreatic Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Acinar Cell</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<mesh_term>Fluorodeoxyglucose F18</mesh_term>
	<criteria>COHORT I ( DOSE ESCALATION ) : histologic proof cancer unresectable , amenable standard therapy , patient refuse standard therapy COHORT II ( MTD ) : metastatic adenocarcinoma pancreas tumor amenable biopsy ; prior systemic treatment metastatic disease allow Absolute neutrophil count ( ANC ) = &gt; 1500/uL Platelet &gt; = 100,000/uL Total bilirubin = &lt; upper limit normal ( ULN ) Aspartate aminotransferase ( AST ) ( serum glutamic oxaloacetic transaminase [ SGOT ] ) = &lt; 3 x ULN Creatinine = &lt; 1.5 x ULN Hemoglobin &gt; = 9.0 g/dL Prothrombin time ( PT ) /international normalize ratio ( INR ) &lt; 1.25 x ULN ( Cohort II [ MTD ] ) Cholesterol &lt; Common Terminology Criteria Adverse Events ( CTCAE ) grade 3 Triglycerides &lt; CTCAE grade 2 Magnesium &gt; = low limit normal ( LLN ) = &lt; ULN Ability provide informed consent Willing return Mayo Clinic follow Life expectancy &gt; = 12 week Cohort II ( MTD ) Translational Research : Willing provide biologic specimen require protocol ; Note : part mandatory translational research component Women childbearing potential : Negative serum pregnancy test do = &lt; 7 day prior registration ; NOTE : female subject pregnant nursing exclude study ; specific mitigation strategy vismodegib toxicity ; however , male patient make aware consent process ; although effect expect reversible discontinuation dosing , longterm effect male fertility exclude time Eastern Cooperative Oncology Group ( ECOG ) performance status ( PS ) 0 , 1 2 Able swallow medication administer Gtube absorb medication Participant agree use acceptable form contraception study 7 month last study drug dose Acceptable form contraception : Latex condom ( always use spermicide ) Diaphragm ( always use spermicide ) Cervical cap ( always use spermicide ) Acceptable form secondary contraception , use along barrier method : Hormonal contraception method , include pill , patch , ring , injection except progestinonly contain pill ( i.e . `` Minipill '' ) Tubal ligation Partner 's vasectomy Intrauterine device ( nonprogesterone T ) Vaginal sponge ( contain spermicide ) Other acceptable form : 100 % commitment abstinence Unacceptable form contraception woman childbearing potential : Oral contraception contain progestin Intrauterine device ( IUD ) progesterone T Female condom Natural family planning ( rhythm method ) breastfeed Fertility awareness Withdrawal Cervical shield Willing smoke Willing complete pill diary day COHORT I ( DOSE ESCALATION ) : Known standard therapy patient 's disease potentially curative definitely capable extend life expectancy Uncontrolled intercurrent illness include , limited , ongoing active infection , symptomatic congestive heart failure , unstable angina pectoris , cardiac arrhythmia , diabetes mellitus psychiatric illness/social situation would limit compliance study requirement Any follow prior therapy : Chemotherapy = &lt; 4 week prior registration Mitomycin C/nitrosoureas = &lt; 6 week prior registration Immunotherapy = &lt; 4 week prior registration Biologic therapy = &lt; 4 week prior registration Radiation therapy = &lt; 4 week prior registration Radiation &gt; 25 % bone marrow Failure fully recover acute , reversible effect prior chemotherapy regardless interval since last treatment New York Heart Association classification III IV Uncontrolled Seizure Disorder Central nervous system ( CNS ) metastases stable least 23 month base imaging , clinical assessment , use steroid , seizure disorder Any following : Pregnant woman Nursing woman This study involve investigational agent whose genotoxic , mutagenic teratogenic effect develop fetus newborn unknown Other concurrent chemotherapy , immunotherapy , radiotherapy , ancillary therapy consider investigational ( utilized nonFood Drug Administration [ FDA ] approve indication context research investigation ) receive investigational agent would consider treatment primary neoplasm Receiving medication substance strong moderate inhibitor cytochrome P450 3A4 ( CPY450 3A4 ) ; use follow strong moderate inhibitor prohibit : Strong Inhibitors CYP3A4 : Indinavir , Nelfinavir , Ritonavir , Clarithromycin , Itraconazole , Ketoconazole , Nefazodone , Saquinavir , Telithromycin Moderate Inhibitors CYP3A4 : Aprepitant , Erythromycin , Fluconazole , Grapefruit juice , Verapamil , Diltiazem Receiving medication substances inducer CYP450 3A4 Inducers CYP3A4 : Efavirenz , Nevirapine , Carbamazepine , Modafinil , Phenobarbital , Phenytoin , Pioglitazone , Rifabutin , Rifampin , St. John 's wort Receiving medication substance strong moderate inhibitor CYP450 CYP2C8 Strong Moderate Inhibitors CYP2C8 : Gemfibrozil , Trimethoprim Receiving medication substances inducer CYP450 2C8 Inducer CYP2C8 : Rifampin Receiving medication substance strong moderate inhibitor CYP450 CYP2C9 Strong Moderate Inhibitors CYP2C9 : Fluconazole , Amiodarone Receiving medication substances inducer CYP450 2C9 Inducers CYP2C9 : Rifampin , Secobarbital Immunocompromised patient ( relate use corticosteroid ) include patient receive highly active antiretroviral therapy ( HAART ) treatment Active malignancy , except nonmelanotic skin cancer carcinomain situ ( e.g . cervix , breast prostate ) ; history prior malignancy , must receive specific treatment ( hormonal therapy ) cancer History myocardial infarction = &lt; 6 month , congestive heart failure require use ongoing maintenance therapy lifethreatening ventricular arrhythmia Abnormalities cornea base history ( e.g. , dry eye syndrome , Sjogren 's syndrome ) , congenital abnormality ( e.g. , Fuch 's dystrophy ) , abnormal slitlamp examination use vital dye ( e.g. , fluorescein , Bengal Rose ) , and/or abnormal corneal sensitivity test ( Schirmer test similar tear production test ) Prior therapy hedgehog inhibitor</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>